ClinicalTrials.gg
RecruitingNCT06450301Updated Nov 3, 2026

Senescent Endometrial Cells in Patients With Thin Endometrial Lining

An observational study in Asherman's Syndrome, Thin Endometrial Lining and Cell Senescence, sponsored by Trio Fertility. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Trio Fertility · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 39 Years
Sex
Female
01

Study summary

The goal of this observational study is to determine if thin endometrial lining that is unresponsive to estrogen might be associated with the presence of senescent cells in patients following long-term use of oral contraceptives. The main question it aims to answer is:

Are there any senescent cells present in thin endometrial lining?

During the luteal phase of the cycle, participants will will undergo:

  • Gynecologic US to measure the endometrial lining thickness and pattern.
  • Endometrial biopsy with Pipelle catheter
Read the detailed description

The investigators hypothesized that senescent cells in the endometrium may be the cause of the failure of thin endometrium to respond to normal growth stimuli such as estrogen.

The outcome that research team anticipate to measure is the percentage of senescent cells in the endometrial biopsies of women with thin endometrium compared to the control group biopsies.

02

Conditions studied

  • Asherman's Syndrome
  • Thin Endometrial Lining
  • Cell Senescence

Browse trials for

03

In context

Gynatresia

99 studies on the registry are indexed under Gynatresia; 22 are open to participants now.

This study's planned enrollment of 100 is above the median of 73 across 12 observational studies indexed under Gynatresia.

Browse Gynatresia studies →

Lead sponsor

Trio Fertility is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

We intend to recruit 30 patients following long-term use of oral contraceptives with known thin endometrial lining (less than 7mm, confirmed in at least two cycles and unresponsive to estrogen-induced growth). We will also recruit 20 women with Asherman's syndrome following D\&C. We will ask each woman to undergo an endometrial biopsy as part of the study. As a control group, we will recruit 50 patients already scheduled to undergo an endometrial biopsy for infertility management (EMMA testing, endometrial scratching for IVF cycles). Endometrial biopsies are standard procedures during infertility investigations. In some cases, we may be able to access archived endometrial samples from women in the control group who agree to participate and who have already had an endometrial biopsy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-39
  • - up to 35
  • Thin endometrium after OCP use
  • Asherman's syndrome
  • Women already undergoing endometrial for infertility testing (eg. EMMA testing)
  • Women with archived endometrial biopsy samples

Exclusion criteria

Exclusion Criteria:

  • Women with systemic disease (Rheumatic disease, DM)
  • Women with coagulopathies
  • Women with active pelvic inflammatory process
  • Uterine anomalies
  • Pregnant women
  • Any hormonal use or IUD
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Thin endometrial lining

    Patients following long-term use of oral contraceptives with known thin endometrial lining (less than 7mm, confirmed in at least two cycles and unresponsive to estrogen-induced growth). We will ask each woman to undergo an endometrial biopsy as part of the study during their luteal phase.

    Procedure: Endometrial Biopsy

  • Asherman's syndrome

    Patients with Asherman's syndrome following Dilation and curettage (D\&C). We will ask each woman to undergo an endometrial biopsy as part of the study during their luteal phase.

    Procedure: Endometrial Biopsy

  • Control

    Patients already scheduled to undergo an endometrial biopsy for infertility management. We will ask each woman to undergo an endometrial biopsy as part of the study during their luteal phase. In some cases, we may be able to access archived endometrial samples from women in the control group who agree to participate and who have already had an endometrial biopsy.

    Procedure: Endometrial Biopsy

Interventions

  • ProcedureEndometrial Biopsy

    An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial biopsies are commonly done to check for the window of implantation, to determine ovulation or for enhancing implantation (procedure called endometrial scratching). For this purpose, we will use a "Pipelle" catheter. This procedure is very common in gynecologic practice and generally considered safe. In most of the cases this procedure is indicated for evaluation of irregular vaginal bleeding, vaginal bleeding in post-menopausal women and for infertility related problems (recurrent implantation failures for example).

06

What researchers measure

Primary outcomes

  1. Senescent cells presence

    Percentage of senescent cells in the endometrial biopsies of women with thin endometrium compared to the control group biopsies.

    Time frame: Through study completion, an average of 3 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Jan 2027 → Sep 2027 and completion Jun 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 10, 2024
StartActual
Sep 11, 2024
Primary completionEst.
Sep 2027was Jan 2027
CompletionEst.
Sep 2027was Jun 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 2027→Sep 2027
Nov 3, 2026
Study completion
Jun 2027→Sep 2027
Nov 3, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Trio Fertility · Toronto, CanadaContact person changed (no phone or email listed)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Jan 2027→Sep 2027
    Study completion Jun 2027→Sep 2027
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Trio Fertility · Toronto, CanadaContact person changed (no phone or email listed)
    + 5 other changes: identifiers, verification date, oversight details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06450301
Lead sponsor
Trio Fertility
Responsible party
Dr. Robert F. Casper (Scientific Director, MD, FRCSC, REI, University of Toronto) — Principal investigator
First posted
Jun 10, 2024
Start date
Sep 11, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion